Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
ODDITY TECH 0CDI.PA-O 0META 11.03MNT.TO 0.69COPX 1.79U.U.TO 0.5SII.TO 2.94IPCO.TO -0.43
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

28.57
+0.60 (2.15%)
as of Aug 25, 2026, 8:00:00 pm Market Open.
582 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconAug 25, 2026, 12:00 am

This summary was created by AI, based on 24 opinions in the last 12 months.

Pfizer Inc. (PFE) has faced challenges following its prominent role during the Covid-19 pandemic, with many experts pointing out the looming patent cliffs and the need for new blockbuster drugs to sustain growth. The company is heavily reliant on its dividends, offering yields between 6% to 8%, which many investors find attractive in a low growth environment. While some view it as a value play due to its low price-to-earnings ratio, others express concerns that it may be a value trap due to uncertain growth prospects. The overall sentiment reflects a cautious approach, favoring the dividend payout amidst worries about drug pipeline sustainability and the impact of recent acquisitions on its future performance.

consensus icon
Consensus
Cautious
valuation icon
Valuation
Undervalued
review icon
Similar
MRK
DON'T BUY

Pfizer Inc(PFE)

Sep 04, 2009
Largest drug company globally. Very strong number of products but along with most of the big pharmaceutical companies there are a large number of drugs that come off patent. About 25% of their earnings comes from one drug, Lipitor and when it comes off patent it will have a big effect on their earnings. There are better places to be.
Photo of Andrew Guy, CFAAndrew Guy, CFAUnlock Rating
$16.39

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
Track your Stocks in your Watch List
DON'T BUY

Pfizer Inc(PFE)

Aug 25, 2009
This is not the one to bet on in this sector. Very cheap, up for a reason. Drug pipeline is not impressive. Have patent issues. (See Top Picks.)
Photo of Karl BergerKarl Berger
No
Unlock Rating
$16.80

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Pfizer Inc(PFE)

Aug 19, 2009
Recently started buying through selling Put options, which would require him to Buy (e.g. at $16). Tide is turning on the sector and he likes it very much. Risks are healthcare reform and patent expirations.
Photo of Ara NalbandianAra Nalbandian
Owned
Unlock Rating
$16.37

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jul 27, 2009
There will continue to be pressure on prices. Also US government is litigation friendly, which can hit them with 1) injury related suits and 2) patent infringement.
Photo of David BaskinDavid Baskin
No
Unlock Rating
$16.62

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Jul 07, 2009
Reflects all the bad news that Lipitor will be going going off patent in a couple of years and its drug pipeline is absolutely barren. In the meantime you get paid 6.5%. Pretty cheap.
Photo of Gavin GrahamGavin Graham
Owned
Unlock Rating
$14.59

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jul 06, 2009
Thinks the pharmaceutical sector will start to do quite well in the next 2 years. It is so negative now in terms of what the government wants to do but historically they have never been able to cut the price of drugs. You are getting 5% to wait.
Photo of Kevin O'LearyKevin O'Leary
Owned
Unlock Rating
$14.57

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jun 12, 2009
Not a fan of big cap pharma and hasn't been for some time. One of the most difficult business models to operate. Regulatory issues are so difficult to overcome between patent expiries and increasingly stringent health regulations and registration processes. (See Top Picks.)
Photo of Charles LannonCharles Lannon
No
Unlock Rating
$14.76

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
SELL

Pfizer Inc(PFE)

Jun 04, 2009
The major pharmaceuticals are not on his top list. Bioteches are where you are going to see innovations. They are the ones coming out with the new drugs and have a better pipeline.
Photo of Matthew McCallMatthew McCall
No
Unlock Rating
$14.64

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

May 06, 2009
Just doesn't seem to be up to right itself. Spinning off a lot of cash but its size limits it from growing.
Photo of Gordon ReidGordon Reid
No
Unlock Rating
$13.91

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Apr 14, 2009
Getting killed by generics. They get sued when they hurt people. Government won't stand up for them when generics can provide health care at a fraction of the price. Prefer TEVA-O
Photo of David BaskinDavid Baskin
No
Unlock Rating
$13.34

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Mar 31, 2009
Has been a difficult stock. Could improve from here however there will be other opportunities in this space you could get more juice from.
Photo of Brett HrybBrett Hryb
Owned
Unlock Rating
$13.62

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Mar 30, 2009
(A Top Pick April 10/08. Down 27.8%.) Paired with Teva (TEVA-Q) as his generic company. Down a little because of their intention to purchase Wyath. Cut their dividend but still gives a healthy yield. Good defensive place.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$13.70

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Mar 26, 2009
Made a good acquisition of Wyeth. Have created value in previous acquisitions. Cut the dividend while making the deal so the stock price fell. This made a lot of sense. The big issue is whether this will fill a hole in their product line. Reasonable dividend and very good balance sheet.
Photo of Paul Harris, CFAPaul Harris, CFA
No
Unlock Rating
$14.38

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Mar 18, 2009
A former glory growth stock. A lot of healthcare products and there is the issue of aging in America but that is offset by many of their expensive premier drugs going generic. Just cut their dividends. Would prefer other pharmaceutical stocks.
Photo of David AbellaDavid Abella
No
Unlock Rating
$14.25

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Feb 24, 2009
(A Top Pick Feb 27/08. Down 40%.)
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$13.59

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
Showing 481 to 495 of 887 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

ATD.TO -0.8$85.19
1523.HK 0$
CSU.TO -20.01$3078.66
NVO 1.74$48.66
PAYC 2.08$231.7

Today's Top Picks

ODDITY T… 0$
CDI.PA-O 0$
META 11.03$570.05
MNT.TO 0.69$69.95
COPX 1.79$96.32

Popular Articles

Latest Sell Signals

ORCL 2.31$144.76
GAW-LSE 0$
BB.TO 0.17$10.79
SHOP.TO 5.21$212.84
IBM 3.15$234.19

Most Recent Experts

Jason Del Vicario

Jason Del Vicario

HollisWealth

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Rick Rule

Rick Rule

Rule Investment Media

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like